Scancell Holdings PLC - Oxford, England-based immunotherapies for treatment of cancer and infectious disease - Says it expands its research & development capabilities with new facilities at Oxford Science Park. The new premises will allow the company to further accelerate the development of its portfolio of immunotherapies.
Chief Executive Officer Lindy Durrant says: "TOSP is the perfect location for Scancell's expansion, with access to an excellent local talent pool as we grow the business. We are excited to be part of the creative and collaborative group of companies located in the Park and look forward to further developing our innovative products at this new site."
Current stock price: 21.00 pence
Year-to-date change: up 52%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Scancell Holdings (SCLP)